Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tolérance du Linézolide Pendant le Régime BPaL Avec Personnalisation de la Posologie Basée Sur la Surveillance Thérapeutique Des Médicaments (TDM) au Cours du Traitement de la Tuberculose Multirésistante

NCT07477119 is registered in ClinicalTrials.gov with Marco Schiuma as lead sponsor.

NCT NCT07477119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07477119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tolérance du Linézolide Pendant le Régime BPaL Avec Personnalisation de la Posologie Basée Sur la Surveillance Thérapeutique Des Médicaments (TDM) au Cours du Traitement de la Tuberculose Multirésistante
Lead sponsor
Marco Schiuma
Phase
Phase 4
Overall status
Recruiting
Start date
April 30, 2026
Completion date
April 30, 2028
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

linezolid, therapeutic drug monitoring (tdm), tuberculosis multi drug resistant active